$EDSA

Edesa Biotech, Inc.

Edesa Biotech is a biopharmaceutical company developing drug candidates for inflammatory and immune-related diseases. Its clinical pipeline focuses on Medical Dermatology and Respiratory. In Medical Dermatology, it is developing EB06, an antibody candidate for vitiligo, and EB01, a topical cream candidate for chronic allergic contact dermatitis that is at the partnering stage. Its Respiratory program includes paridiprubart, an antibody candidate for acute respiratory distress syndrome, which is also being evaluated in a U.S. government-funded study. Edesa is exploring additional uses for paridiprubart and development of other candidates. Edesa acquires and in-licenses drug candidates, then develops them for potential regulatory approval and commercialization. It may commercialize approved products directly or through licensing and strategic partners. It also grants product rights to partners and receives royalties on licensed product sales. Edesa is headquartered in Toronto.

AlphAI earnings readFiscal 3rd Quarter 2026 · AUG 13Edesa Biotech Reports Fiscal 3rd Quarter 2026 ResultsVerdict: mixed

Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.

5
0
0

No SEC Form 4 filings for $EDSA in the last 30 days.

See all $EDSA insider activity →
Med

Edesa Biotech, Inc. announced that the European Commission has granted orphan designation to its investigational drug paridiprubart for the treatment of…

Edesa Biotech, Inc. (EDSA) filed an SEC Form 8-K — Other Events. Item 8.01. Other Events. On November 17, 2026, Edesa Biotech, Inc. (the “Company”) announced that the European Commission has granted orphan designation to its investigational drug paridiprubart for the treatment of Acute Respiratory Distress Syndrome (“ARDS”). The designation fo

Edesa Biotech, Inc. (EDSA) Gets EU Orphan Designation for ARDS Drug

Edesa Biotech (EDSA) received EU orphan designation for paridiprubart, a drug for ARDS. The decision was based on Phase 2/3 data showing significant survival improvements, though no effect size was disclosed. This is a regulatory milestone for the company's clinical-stage program.

Healthcare Stocks Rally: EDSA And DCTH Jump 30%, VIR And IMVT Also Gain

Edesa Biotech (EDSA) and Delcath Systems (DCTH) shares rose 30% after signing a licensing deal and reporting strong Q3 results, respectively. Immunovant (IMVT) and Vir Biotechnology (VIR) shares gained 13% and 14% following positive clinical trial data. EDSA received $12M upfront, DCTH raised FY26 revenue outlook, IMVT met primary endpoint, and VIR showed undetectable HDV RNA in 28 patients.

EDSA sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 5 news stories mentioning EDSA (Edesa Biotech, Inc.). Coverage has skewed bullish: 5 bullish, 0 neutral, and 0 bearish.

Recent EDSA coverage spans regulation, corporate actions and market movers.

What's driving EDSA

  • Orphan designation is a positive regulatory milestone that can improve development economics and strengthen the path toward EU approval.

    SEC EDGAR 8-K · Nov 17, 2026

  • Orphan designation can strengthen the regulatory and commercial pathway, but it is not an approval and does not guarantee eventual marketing authorization.

    tradingview.com · Nov 17, 2026

  • Deal terms and Japan commercialization rights are likely to re-rate near-term value and de-risk development funding for EDSA.

    rttnews.com · Nov 9, 2026

  • The agreement provides immediate cash and significant upside from future milestones, likely boosting EDSA's valuation.

    SEC EDGAR 8-K · Nov 9, 2026

  • The cash infusion and future royalty potential are likely to boost EDSA's share price.

    investing.com · Nov 9, 2026

AlphAI scores every news story that mentions EDSA with an AI model for sentiment and relevance, and aggregates insider trades from Edesa Biotech, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $EDSA

Score
$EDSAMedClinical / regulatory

Edesa Biotech, Inc. announced that the European Commission has granted orphan designation to its investigational drug paridiprubart for the treatment of…

Edesa Biotech, Inc. (EDSA) filed an SEC Form 8-K — Other Events. Item 8.01. Other Events. On November 17, 2026, Edesa Biotech, Inc. (the “Company”) announced that the European Commission has granted orphan designation to its investigational drug paridiprubart for the treatment of Acute Respiratory Distress Syndrome (“ARDS”). The designation fo

$EDSAMedAI 8/10

Healthcare Stocks Rally: EDSA And DCTH Jump 30%, VIR And IMVT Also Gain

Edesa Biotech (EDSA) and Delcath Systems (DCTH) shares rose 30% after signing a licensing deal and reporting strong Q3 results, respectively. Immunovant (IMVT) and Vir Biotechnology (VIR) shares gained 13% and 14% following positive clinical trial data. EDSA received $12M upfront, DCTH raised FY26 revenue outlook, IMVT met primary endpoint, and VIR showed undetectable HDV RNA in 28 patients.

$EDSAMedContract· supplier · $12M

Edesa Biotech, Inc. (EDSA): Entry into a Material Definitive Agreement

Edesa Biotech, Inc. (EDSA) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EXHIBIT 99.1 Edesa Biotech Announces Agreement with KYORIN Pharmaceutical to Develop and Commercialize Paridiprubart in Japan Deal valued at more than $140 million in upfront and potential milestone payments, plus double-digit royalties. Kyorin obtains exclusive rights to develop

Edesa Biotech, Inc. (EDSA): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Edesa Biotech, Inc. (EDSA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 23, 2026, the Board of Directors (the “Board”) of Edesa Biotech, Inc. (the “Company”), upon the recommendation o

$EDSAMedAI 8/10Clinical / regulatory

Edesa Biotech, Inc. reported that the U.S. Food and Drug Administration has cleared the Company's Investigational New Drug application for its Phase 2…

Edesa Biotech, Inc. (EDSA) filed an SEC Form 8-K — Other Events. Item 8.01. Other Events. On October 15, 2026, Edesa Biotech, Inc. (the “Company”) reported that the U.S. Food and Drug Administration (“FDA”) has cleared the Company's Investigational New Drug (“IND”) application for its Phase 2 clinical study of EB06 in vitiligo, enabling the Co

$EDSAMedAI 8/10

FDA clears a study of patchy skin color loss to expand to U.S. sites. Enrollment is expected next quarter.

Edesa Biotech (EDSA) received FDA clearance to expand its Phase 2 vitiligo study to U.S. sites, with enrollment expected next quarter. Topline data is anticipated for Q4 2027. The study evaluates EB06, a monoclonal antibody targeting CXCL10, in 80 adults with moderate-to-severe vitiligo. Edesa aims to report results in late 2027, marking a key milestone for its vitiligo program.

Related tickers